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ABSTRACT 
Despite its low incidence, stent thrombosis (ST) is one of the most dreaded complications of percutaneous coro-
nary intervention. Endeavor (Medtronics Europe SA) is a new zotarolimus-eluting stent (ZES) with a favorable 
safety profile that was reported in early and ongoing trials. However, few lethal stent thromboses related to this new 
drug eluting stent (DES) have been reported. We experienced a case of simultaneous subacute ZES thromboses, 
6 days after stent implantations in the proximal left anterior descending artery and the proximal right coronary 
artery (RCA). (Korean Circ J 2010;40:243-246) 
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Introduction 
 
After the drug eluting stent (DES) was invented, the 
incidence of in-stent restenosis (ISR) was significantly 
reduced, while stent thrombosis (ST) remained a serious 
complication of intracoronary stent implantation. Un-
like restenosis, ST is rare, but, once developed, almost 
one-third to one-half of all occurrences result in death.
1) 
ST can develop immediately or late (over one year after 
the stent implantation).
2) Although the mechanism is 
not fully understood, incomplete neointimal coverage 
over stent struts is thought to play a role in ST.
3) 
 
Case 
 
A 70-year-old woman visited the emergency room with 
typical chest pain. She had undergone mastectomy for 
left breast cancer 30 years earlier and had hyperten-
sion and diabetes mellitus for 10 years. The electrocar-
diogram (ECG) showed ST segment elevation of 1 mm 
and Q waves in the II, III, and aVF leads. Chest radio-
graphy and 2-D echocardiography showed mild pul-
monary congestion and a regional wall motion abnor-
mality in the inferior wall. Serum troponin I and crea-
tine kinase-MB (CK-MB) levels were 0.69 ng/mL and 
60.1 ng/mL, respectively. 
Aspirin (200 mg) and clopidogrel (300 mg) were ad-
ministered before emergency coronary angiography, and 
low molecular weight heparin was administered subcu-
taneously. Critical stenosis at the proximal segment of 
the right coronary artery (RCA) was noted with Th-
rombolysis in Myocardial Infarction (TIMI) 3 flow, and 
severe stenosis in the proximal segment of the left an-
terior descending coronary artery (LAD) was observed 
(Fig. 1A and B).  
An Endeavor stent (Medtronic Europe SA, 2.75×30 
mm) was implanted in the infarct-related RCA after 
pre-dilatation (2.0×30 mm, 10 atm over 10 seconds) 
without acute complication. As the patient was hemo-
dynamically stable and chest pain was resolved, subse-
quent intervention for the LAD stenosis was chosen. 
Another Endeavor stent (2.75×14 mm) was implanted 
after pre-dilatation (2.5×20 mm, 9 atm over 10 seconds) 
in the proximal segment of the LAD. During the pro-
cedure, the patient’s vital signs were stable and the chest 
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pain disappeared (Fig. 1C and D). She was transferred 
to the general ward after careful observation in the in-
tensive coronary care unit. Aspirin (100 mg) and clo-
pidogrel (75 mg) were administered daily after stent im-
plantation.  
On the sixth day after stent implantation, sudden 
ventricular tachycardia followed by ventricular fibrill-
ation developed along with chest pain and dyspnea. 
The patient received advanced cardiac life support, the 
administration of low molecular weight heparin was re-
sumed, and emergency coronary angiography was per-
formed under the tentative diagnosis of subacute ST 
(Fig. 2A and B).  
Coronary angiography showed total occlusion of the 
previously implanted stents at both the proximal LAD 
and RCA segments despite the appropriate dual anti-
platelet treatment. 
Before revascularization, a temporary pacemaker and 
an intra-aortic balloon pulsation (IABP) catheter were 
inserted. The LAD was re-canalized with simple balloon 
dilatation and the RCA was subsequently re-canalized. 
Successful revascularization was achieved and blood 
flow resumed to TIMI 3 in both arteries. After she was 
transferred to the intensive coronary care unit, vital signs 
were stabilized and the IABP was removed the follow-
ing day. The dose of aspirin and clopidogrel was not 
increased but cilostazol (100 mg bid) was added after 
ST. Because acute renal failure developed and the res-
piratory support with mechanical ventilation was pro-
longed, her discharge was delayed for two months but 
she was without further ischemic events.   
 
Discussion 
 
Sirolimus and paclitaxel have been the most widely 
used coating agents on DESs, and the new zotarolimus-
eluting stent (ZES) was developed with favorable safety 
and efficacy for inhibiting neointimal hyperplasia com-
Fig. 1. Coronary angiogram showing critical stenosis in the proximal LAD (A) and the proximal segment of the RCA (B); recovered lu-
minal patency after revascularization with zotarolimus-eluting stents in each artery (C and D). LAD: left anterior descending coronary ar-
tery, RCA: right coronary artery. 
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pared to bare metal stents in early trials.
4)5) 
Since commercial availability of the new DESs, a few 
cases of ZES thrombosis have been reported.
6)7) Moreover, 
simultaneous subacute multi-vessel ST of ZES stents des-
pite the administration of a substantial number of anti-
platelet agents is very rare.
8)9) 
According to a randomized, controlled study with si-
rolimus eluting stents, the predictors for ST are advanc-
ed age, premature anti-platelet discontinuation, clopi-
dogrel resistance, insulin-dependent diabetes, acute co-
ronary syndrome, low ejection fraction, moderate or 
heavy calcification, multivessel disease, post procedural 
TIMI <3, and a totally occluded lesion as the first ma-
nifestation.
10) The patient in this report was an elderly 
person with type 2 diabetes mellitus, presenting with ac-
ute coronary syndrome.   
We pre-dilated stenotic lesions and carefully measured 
reference diameters of the arteries before the selection 
of appropriate stents. Post-dilatation with a stent bal-
loon was performed to avoid under-dilatation or ma-
lapposition. Therefore, we believe that simultaneous th-
rombosis of different arteries suggest a systemic, rather 
than a local cause. A potential cause of these fatal events 
was the incomplete coverage of anti-platelet agents for 
systemic thrombogenicity such as improper dosage or 
resistance to the anti-platelet agents. A previous report 
showed that up to 25% of patients with myocardial in-
farction associated with ST-segment elevation were re-
sistant to clopidogrel.
11) Unfortunately, we could not as-
certain the resistance to aspirin or clopidogrel in our pa-
tient because the test was unavailable by the time of the 
adverse event and the patient was not compliant later on. 
In summary, we experienced a case of very rare mul-
tivessel ST of a ZESs and expect this problem to be solv-
ed as more experience with ZESs accumulate. 
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